文献速递骨质疏松与代谢性骨病创伤骨科

荷兰65岁以上人群中抗抑郁药或苯二氮䓬类药物使用与后续骨折风险之间的关联

Association between use of antidepressants or benzodiazepines and the risk of subsequent fracture among those aged 65+ in the Netherlands.
PubMed 文献 · Osteoporos Int · 2018-08-15

该队列研究利用荷兰PHARMO数据库网络,纳入2002至2011年间4854例65岁以上首次发生主要骨质疏松性骨折的患者(其中1766例髋部骨折),评估抗抑郁药或苯二氮䓬类使用与后续主要骨质疏松性骨折风险的关联。结果显示,骨折后1年内当前使用抗抑郁药与后续骨折风险升高相关(校正HR 2.17,95%CI 1.37-3.43),而当前使用苯二氮䓬类未见关联。作者结论认为主要骨质疏松性骨折后使用抗抑郁药应谨慎。

要点

  • 主要骨质疏松性骨折后1年内,15%的患者被配发抗抑郁药,31%被配发苯二氮䓬类。
  • 骨折后1年内当前使用抗抑郁药与后续骨折风险升高相关,校正HR 2.17(95%CI 1.37-3.43)。
  • 当前使用苯二氮䓬类与后续骨折风险无显著关联,1年内校正HR 1.18(95%CI 0.76-1.81)。

核心结论

  • 该研究提供证据表明,主要骨质疏松性骨折后使用抗抑郁药应谨慎。
  • 该研究为临床医生评估患者后续骨折风险提供了所需见解。

研究设计与样本

  • 采用荷兰PHARMO数据库网络进行的队列研究。
  • 2002至2011年间,共4854例65岁以上患者发生首次主要骨质疏松性骨折,其中1766例发生髋部骨折。
  • 使用Cox比例风险模型计算发病率与校正风险比。

主要发现

  • 主要骨质疏松性骨折后1年内,15%(95%CI 13.7-15.7)的患者被配发抗抑郁药,31%(95%CI 30.1-32.8)被配发苯二氮䓬类。
  • 主要骨质疏松性骨折后1年内当前使用抗抑郁药与后续骨折相关,校正HR 2.17(95%CI 1.37-3.43)。
  • 抗抑郁药的近期使用和过去使用也与后续骨折风险升高相关。
  • 纳入完整随访期时,仅当前使用抗抑郁药与主要骨质疏松性骨折后后续骨折相关,校正HR 1.48(95%CI 1.06-2.06)。
  • 当前使用苯二氮䓬类与主要骨质疏松性骨折后1年内骨折风险升高无关(校正HR 1.18,95%CI 0.76-1.81),与完整随访期骨折风险升高也无关(校正HR 1.18,95%CI 0.90-1.55)。

临床怎么用

  • 作者结论认为,主要骨质疏松性骨折后使用抗抑郁药应谨慎。
  • 作者指出,该研究为临床医生评估患者后续骨折风险提供了所需见解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This is the first study to examine the association between antidepressant and benzodiazepine use following a MOF and risk of subsequent fracture in those 65+. Using national data, drug use following MOF showed that the 1-year fully adjusted risk of subsequent MOF in those on antidepressants was more than doubled. INTRODUCTION: We evaluated the association between the use of antidepressants or benzodiazepines and the risk of a subsequent major osteoporotic fracture. METHODS: A cohort study was performed using the Dutch PHARMO Database Network. Between 2002 and 2011, a total of 4854 patients sustained a first major osteoporotic fracture after the age of 65 years, of which 1766 sustained a hip fracture. Incidence rates and adjusted hazard ratios were calculated using Cox proportional hazards models. RESULTS: Within 1 year following a major osteoporotic fracture, 15% (95% CI 13.7-15.7) and 31% (95% CI 30.1-32.8) of patients were dispensed an antidepressant or benzodiazepine, respectively. Current use of antidepressants in the first year following a major osteoporotic fracture was associated with subsequent fracture (adjusted HR 2.17 (95% CI 1.37-3.43)). Recent and past use of antidepressants were also associated with an increased risk of subsequent fracture. When the complete follow-up period was included, only the current use of antidepressants was associated with subsequent fracture following a major osteoporotic fracture (adjusted HR 1.48; 95% CI 1.06-2.06). Current benzodiazepine use was not associated with an increased risk of fracture within 1 year following a major osteoporotic fracture (adjusted HR 1.18; 95% CI 0.76-1.81) or during the complete follow-up period (adjusted HR 1.18; 95% CI 0.90-1.55). CONCLUSION: This study provides evidence that antidepressants should be used with caution following a major osteoporotic fracture. It provides needed insights that can be used to inform clinicians when assessing subsequent fracture risk in patients.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. van de Ven LI, Klop C, Overbeek JA, et al. Association between use of antidepressants or benzodiazepines and the risk of subsequent fracture among those aged 65+ in the Netherlands. Osteoporos Int. 2018. PMID: 30112636. doi:10.1007/s00198-018-4632-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。